Insulin-lowering agents in the management of polycystic ovary syndrome

被引:229
作者
De Leo, V [1 ]
la Marca, A [1 ]
Petraglia, F [1 ]
机构
[1] Univ Siena, Policlin Scotte, Inst Obstet & Gynecol, Dept Pediat Obstet & Reprod Med, I-53100 Siena, Italy
关键词
D O I
10.1210/er.2002-0015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) is a medical condition that has brought multiple specialists together. Gynecologists, endocrinologists, cardiologists, pediatricians, and dermatologists are all concerned with PCOS patients and share research data and design clinical trials to learn more about the syndrome. Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder. Hyperinsulinemia associated with insulin resistance has been causally linked to all features of the syndrome, such as hyperandrogenism, reproductive disorders, acne, hirsutism, and metabolic disturbances. Women with PCOS should be evaluated for cardiovascular risk factors, such as lipid profile and blood pressure. Modification of diet and lifestyle should be suggested to those who are obese. Several insulin-lowering agents have been tested in the management of PCOS. In particular, metformin is the only drug currently in widespread clinical use for treatment of PCOS. In a high percentage of patients, treatment with metformin is followed by regularization of menstrual cycle, reduction in hyperandrogenism and in cardiovascular risk factors, and improvement in response to therapies for induction of ovulation.
引用
收藏
页码:633 / 667
页数:35
相关论文
共 379 条
  • [1] Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin
    Abbasi, F
    Carantoni, M
    Chen, YDI
    Reaven, GM
    [J]. DIABETES CARE, 1998, 21 (08) : 1301 - 1305
  • [2] Can metformin reduce insulin resistance in polycystic ovary syndrome?
    Acbay, O
    Gundogdu, S
    [J]. FERTILITY AND STERILITY, 1996, 65 (05) : 946 - 949
  • [3] ACHARD MC, 1921, B ACAD NATL MED, V86, P51
  • [4] Insulin, androgens, and obesity in women with and without polycystic ovary syndrome:: a heterogeneous group of disorders
    Acién, P
    Quereda, F
    Matallín, P
    Villarroya, E
    López-Fernández, JA
    Acién, M
    Mauri, M
    Alfayate, R
    [J]. FERTILITY AND STERILITY, 1999, 72 (01) : 32 - 40
  • [5] INSULIN ENHANCEMENT OF LUTEINIZING-HORMONE AND FOLLICLE-STIMULATING-HORMONE RELEASE BY CULTURED PITUITARY-CELLS
    ADASHI, EY
    HSUEH, AJW
    YEN, SSC
    [J]. ENDOCRINOLOGY, 1981, 108 (04) : 1441 - 1449
  • [6] INSULIN-LIKE GROWTH-FACTORS AS INTRAOVARIAN REGULATORS OF GRANULOSA-CELL GROWTH AND FUNCTION
    ADASHI, EY
    RESNICK, CE
    DERCOLE, AJ
    SVOBODA, ME
    VANWYK, JJ
    [J]. ENDOCRINE REVIEWS, 1985, 6 (03) : 400 - 420
  • [7] Impact of family history of diabetes on the assessment of β-cell function
    Alford, FP
    Henriksen, JE
    Rantzau, C
    Vaag, A
    Hew, LF
    Ward, GM
    Beck-Nielsen, H
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1998, 47 (05): : 522 - 528
  • [8] Cardiovascular consequences of polycystic ovary syndrome
    Amowitz, LL
    Sobel, BE
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (02) : 439 - +
  • [9] INCREASED INSULIN SENSITIVITY AND FIBRINOLYTIC CAPACITY AFTER DIETARY INTERVENTION IN OBESE WOMEN WITH POLYCYSTIC-OVARY-SYNDROME
    ANDERSEN, P
    SELJEFLOT, I
    ABDELNOOR, M
    ARNESEN, H
    DALE, PO
    LOVIK, A
    BIRKELAND, K
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (05): : 611 - 616
  • [10] Anderson KE, 1997, CANCER, V79, P494, DOI 10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.3.CO